Zacks Research Issues Positive Estimate for Revvity Earnings

Revvity, Inc. (NYSE:RVTY) – Zacks Research upped their FY2024 EPS estimates for Revvity in a research note issued on Monday, November 25th. Zacks Research analyst R. Department now forecasts that the company will post earnings per share of $4.84 for the year, up from their previous estimate of $4.74. The consensus estimate for Revvity’s current full-year earnings is $4.85 per share. Zacks Research also issued estimates for Revvity’s Q4 2024 earnings at $1.36 EPS, Q3 2025 earnings at $1.28 EPS, Q4 2025 earnings at $1.46 EPS, Q1 2026 earnings at $1.33 EPS and Q3 2026 earnings at $1.42 EPS.

Revvity (NYSE:RVTY) last announced its quarterly earnings data on Monday, November 4th. The company reported $1.28 EPS for the quarter, topping analysts’ consensus estimates of $1.13 by $0.15. The company had revenue of $684.10 million during the quarter, compared to the consensus estimate of $679.66 million. Revvity had a return on equity of 7.42% and a net margin of 9.34%. The company’s quarterly revenue was up 2.1% on a year-over-year basis. During the same quarter last year, the company earned $1.18 EPS.

A number of other analysts have also recently weighed in on RVTY. Wells Fargo & Company assumed coverage on shares of Revvity in a research note on Tuesday, August 27th. They issued an “equal weight” rating and a $130.00 target price on the stock. Sanford C. Bernstein dropped their target price on Revvity from $150.00 to $145.00 and set an “outperform” rating for the company in a report on Tuesday, November 5th. JPMorgan Chase & Co. raised their target price on Revvity from $105.00 to $120.00 and gave the stock a “neutral” rating in a research report on Tuesday, July 30th. Raymond James upped their price target on Revvity from $144.00 to $146.00 and gave the company an “outperform” rating in a research report on Tuesday, November 5th. Finally, Robert W. Baird boosted their target price on shares of Revvity from $136.00 to $138.00 and gave the company an “outperform” rating in a research note on Tuesday, November 5th. Seven analysts have rated the stock with a hold rating, nine have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $131.73.

Revvity Trading Up 0.4 %

Shares of RVTY stock opened at $115.14 on Wednesday. The firm has a fifty day moving average of $120.22 and a 200-day moving average of $115.89. The stock has a market cap of $14.01 billion, a price-to-earnings ratio of 55.62, a P/E/G ratio of 2.80 and a beta of 1.05. Revvity has a 52-week low of $86.30 and a 52-week high of $129.50. The company has a debt-to-equity ratio of 0.40, a quick ratio of 2.97 and a current ratio of 3.56.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Price T Rowe Associates Inc. MD raised its holdings in Revvity by 1.3% in the first quarter. Price T Rowe Associates Inc. MD now owns 168,547 shares of the company’s stock worth $17,698,000 after purchasing an additional 2,153 shares during the period. California State Teachers Retirement System raised its stake in Revvity by 0.8% during the 1st quarter. California State Teachers Retirement System now owns 196,168 shares of the company’s stock worth $20,598,000 after buying an additional 1,484 shares during the period. Jane Street Group LLC lifted its holdings in Revvity by 516.4% during the first quarter. Jane Street Group LLC now owns 453,343 shares of the company’s stock worth $47,601,000 after acquiring an additional 379,802 shares in the last quarter. Wahed Invest LLC lifted its holdings in shares of Revvity by 13.6% during the 1st quarter. Wahed Invest LLC now owns 2,399 shares of the company’s stock valued at $252,000 after purchasing an additional 288 shares in the last quarter. Finally, Virtu Financial LLC bought a new stake in shares of Revvity during the first quarter worth $1,214,000. Institutional investors own 86.65% of the company’s stock.

Insider Activity at Revvity

In other news, insider Tajinder S. Vohra sold 2,154 shares of the business’s stock in a transaction dated Wednesday, October 9th. The stock was sold at an average price of $121.73, for a total transaction of $262,206.42. Following the completion of the transaction, the insider now directly owns 19,652 shares in the company, valued at approximately $2,392,237.96. The trade was a 9.88 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.60% of the stock is owned by company insiders.

Revvity Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, February 7th. Stockholders of record on Friday, January 17th will be paid a dividend of $0.07 per share. This represents a $0.28 annualized dividend and a dividend yield of 0.24%. The ex-dividend date of this dividend is Friday, January 17th. Revvity’s dividend payout ratio (DPR) is presently 13.53%.

Revvity declared that its Board of Directors has approved a stock buyback program on Monday, November 4th that allows the company to buyback $1.00 billion in shares. This buyback authorization allows the company to reacquire up to 6.5% of its stock through open market purchases. Stock buyback programs are typically a sign that the company’s management believes its stock is undervalued.

Revvity Company Profile

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.